Correlation Between Lyra Therapeutics and Scopus Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyra Therapeutics and Scopus Biopharma, you can compare the effects of market volatilities on Lyra Therapeutics and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Scopus Biopharma.

Diversification Opportunities for Lyra Therapeutics and Scopus Biopharma

-0.06
  Correlation Coefficient

Good diversification

The 3 months correlation between Lyra and Scopus is -0.06. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Scopus Biopharma go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and Scopus Biopharma

If you would invest  18.00  in Lyra Therapeutics on October 26, 2024 and sell it today you would earn a total of  1.00  from holding Lyra Therapeutics or generate 5.56% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy5.56%
ValuesDaily Returns

Lyra Therapeutics  vs.  Scopus Biopharma

 Performance 
       Timeline  
Lyra Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Scopus Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Lyra Therapeutics and Scopus Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lyra Therapeutics and Scopus Biopharma

The main advantage of trading using opposite Lyra Therapeutics and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.
The idea behind Lyra Therapeutics and Scopus Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Complementary Tools

Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
CEOs Directory
Screen CEOs from public companies around the world
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments